Novo Nordisk A/s

Xujia Zhang

Henning Thoegersen

Yi Wang

Xiang Gao

Hongtao Guan

Kristian Tage Hansen

Lars Fogh Iversen

Kristian Sass-Oerum

Sebastian Beck Joergensen

Per Noergaard

Patrick William Garibay

Tina Moeller Tagmose

Birgit Wieczorek

Peter Kresten Nielsen

Kilian Waldemar Conde Frieboes

Yun Liu

Weiwei Tong

Kristian Sass Bak-Jensen

Henning THØGERSEN

Helle Fabricius Woeldicke

Helle Fabricius Woeldike

Jishu Wang

Helle Fabricius WÖLDICKE

Helle WÖLDIKE

The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide and an N-terminal amino acid extension, wherein said extension consists of 3 to 36 amino acid residues and where the compound has a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.

MIC-1 compounds and use thereof

The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor wherein the amino acid extension comprises 3 to 36 amino acid residues and where the MIC-1 polypeptide and the N-terminal amino acid extension together have a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.

MIC-1 compounds and uses thereof

Analogs of FGF21 carrying a modifying, substituted ethylene or benzyl group can be used for treatment or prevention of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD).

N-terminal modified FGF21 compounds

The present invention is related to novel mammalian enterokinase analogues such as mammalian enterokinase light chain analogues and methods of making such. Also described herein is a method for cleaving proteins having an enterokinase cleavage site.

Modified enterokinase light chain

Growing community of inventors

Beijing, China

Xujia Zhang